These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA. Catarino M; Conde R Scand J Clin Lab Invest Suppl; 1991; 207():43-6. PubMed ID: 1780689 [TBL] [Abstract][Full Text] [Related]
5. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. Fioretti P; Gadducci A; Ferdeghini M; Prontera C; Malagnino G; Facchini V; Mariani G; Bianchi R Gynecol Oncol; 1992 Feb; 44(2):155-60. PubMed ID: 1544592 [TBL] [Abstract][Full Text] [Related]
6. Tumor-associated trypsin inhibitor, TATI, in gastrointestinal cancer and related benign diseases. Piantino P; Arosaio E Scand J Clin Lab Invest Suppl; 1991; 207():67-9. PubMed ID: 1780697 [TBL] [Abstract][Full Text] [Related]
7. Postoperative CEA is a better prognostic marker than CA19-9, hCGβ or TATI after resection of colorectal liver metastases. Peltonen R; Österlund P; Lempinen M; Nordin A; Stenman UH; Isoniemi H Tumour Biol; 2018 Jan; 40(1):1010428317752944. PubMed ID: 29378497 [TBL] [Abstract][Full Text] [Related]
8. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder. Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540 [TBL] [Abstract][Full Text] [Related]
9. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gadducci A; Ferdeghini M; Prontera C; Moretti L; Mariani G; Bianchi R; Fioretti P Gynecol Oncol; 1992 Feb; 44(2):147-54. PubMed ID: 1312052 [TBL] [Abstract][Full Text] [Related]
10. TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer. Medl M; Ogris E; Peters-Engl C; Leodolter S Br J Cancer; 1995 May; 71(5):1051-4. PubMed ID: 7734298 [TBL] [Abstract][Full Text] [Related]
11. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242. Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604 [TBL] [Abstract][Full Text] [Related]